Anti-tumor necrosis factor therapy and cancer risk in patients with autoimmune disorders

Arthritis Care and Research

Volumn 62, Issue 7, 2010, Pages 1024-1028

  Onel, Karen B ^a   Onel, Kenan ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

AUTOIMMUNE DISEASE; CANCER RISK; CARCINOGENESIS; DRUG EFFECT; HUMAN; MALIGNANT NEOPLASTIC DISEASE; REVIEW;

ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; HUMANS; IMMUNOCOMPROMISED HOST; NEOPLASMS; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954267440     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20228     Document Type: Review

References (50)

1. Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 2001;76:653-6.
2. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists. Arthritis Rheum 2007;56:1125-33.
3. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148-55.
4. Wood KL, Hage CA, Knox KS, Kleiman MB, Sannuti A, Day RB, et al. Histoplasmosis after treatment with anti-tumor necrosis factor-α therapy. Am J Respir Crit Care Med 2003;167: 1279-82.
5. Bickston SJ, Lichtenstein GR, Arseneau KO, Cohen RB, Cominelli F. The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology 1999;117: 1433-7.
6. Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor α receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol 2001;45:953-6.
7. Ziakas PD, Giannouli S, Tzioufas AG, Voulgarelis M. Lymphoma development in a patient receiving anti-TNF therapy. Haematologica 2003;88:e108-9.
8. Pfistershammer K, Petzelbauer P, Stingl G, Mastan P, Chott A, Jager U, et al. Methotrexate-induced primary cutaneous diffuse large B-cell lymphoma with an 'angiocentric' histological morphology. Clin Exp Dermatol 2010;35:59-62.
9. Hellgren K, Smedby KE, Feltelius N, Baecklund E, Askling J. Do rheumatoid arthritis and lymphomas share risk factors? A comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis. Arthritis Rheum 2010;62: 1252-8.
10. Landgren O, Engels EA, Pfeiffer RM, Gridley G, Mellemkjaer L, Olsen JH, et al. Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst 2006;98:1321-30.
11. Gono T, Shimojima Y, Hoshi K, Yamamoto K, Tokuda T, Shikama N, et al. Malignant lymphoma associated with rheumatoid arthritis, developing shortly after initiation of oral methotrexate. Intern Med 2004;43:135-8.
12. Demirkaya E, Cok I, Durmaz E, Ulutas OK, Ayaz NA, Besbas N, et al. Genotoxicity of anti-tumor necrosis factor therapy in patients with juvenile idiopathic arthritis. Arthritis Care Res 2010;62:73-7.
13. Dhawan A, Bajpayee M, Parmar D. Comet assay: a reliable tool for the assessment of DNA damage in different models. Cell Biol Toxicol 2009;25:5-32.
14. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85
15. Thayu M, Markowitz JE, Mamula P, Russo PA, Muinos WI, Baldassano RN. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 2005;40: 220-2.
16. Food and Drug Administration. Early communication about an ongoing safety review of tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, and Cimzia). 2008. URL: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm070725. htm.
17. Food and Drug Administration. Questions and answers: TNF blockers 8/25/2009. 2009. URL: http://www.fda.gov/Drugs/ DrugSafety/ PostmarketDrugSafetyInformationforPatientsand Providers/ DrugSafetyInformationforHeathcareProfessionals/ ucm180694.htm.
18. Li J, Thompson TD, Miller JW, Pollack LA, Stewart SL. Cancer incidence among children and adolescents in the United States, 2001-2003. Pediatrics 2008;121:e1470-7.
19. Food and Drug Administration. FDA: cancer warnings required for TNF blockers. 2009. URL: http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ 2009/ucm175 803.htm.
20. Mariette X, Tubach F, Bagheri H, Bardet M, Berthelot JM, Gaudin P, et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 2010;69:400-8.
21. Caspersen S, Elkjaer M, Riis L, Pedersen N, Mortensen C, Jess T, et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 2008;6:1212-7.
22. Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor α therapies: does the risk change with the time since start of treatment? Arthritis Rheum 2009;60:3180-9.
23. Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000;88:497-502.
24. Hakulinen T, Knekt P, Uotila O, Isomaki H. Similar survival rates for rheumatoid and non-rheumatoid cancer patients. Scand J Rheumatol 1986;15:285-9. (Pubitemid 17225960)
25. Hazleman BL. The comparative incidence of malignant disease in rheumatoid arthritics exposed to different treatment regimens. Ann Rheum Dis 1982;41 Suppl 1:12-7.
26. Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 1997;40:1580-6.
27. Boelaert K, Newby PR, Simmonds MJ, Holder RL, Carr-Smith JD, Heward JM, et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med 2010;123:183e1-9.
28. Stagi S, Giani T, Simonini G, Falcini F. Thyroid function, autoimmune thyroiditis and coeliac disease in juvenile idiopathic arthritis. Rheumatology (Oxford) 2005;44:517-20.
29. Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev 2006;15:2069-77.
30. Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 2009;68:1177-83.
31. Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008;10:R45.
32. Ekstrom K, Hjalgrim H, Brandt L, Baecklund E, Klareskog L, Ekbom A, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 2003;48:963-70.
33. Mellemkjaer L, Pfeiffer RM, Engels EA, Gridley G, Wheeler W, Hemminki K, et al. Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma. Arthritis Rheum 2008;58:657-66.
34. Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005;52:1481-90.
35. Schultz DR, Harrington WJ Jr. Apoptosis: programmed cell death at a molecular level. Semin Arthritis Rheum 2003;32: 345-69.
36. Straus SE, Jaffe ES, Puck JM, Dale JK, Elkon KB, Rosen-Wolff A, et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 2001;98:194-200.
37. Ehrenfeld M, Abu-Shakra M, Buskila D, Shoenfeld Y. The dual association between lymphoma and autoimmunity. Blood Cells Mol Dis 2001;27:750-6.
38. Till M, Rapson N, Smith PG. Family studies in acute leukaemia in childhood: a possible association with autoimmune disease. Br J Cancer 1979;40:62-71. (Pubitemid 9225978)
39. Weyand CM, Seyler TM, Goronzy JJ. B cells in rheumatoid synovitis. Arthritis Res Ther 2005;7 Suppl 3:S9-12.
40. Emilie D, Zou W, Fior R, Llorente L, Durandy A, Crevon MC, et al. Production and roles of IL-6, IL-10, and IL-13 in B-lymphocyte malignancies and in B-lymphocyte hyperactivity of HIV infection and autoimmunity. Methods 1997;11:133-42.
41. Lan Q, Zheng T, Rothman N, Zhang Y, Wang SS, Shen M, et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 2006;107: 4101-8.
42. Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, Smith MT, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006;7:27-38.
43. Eguchi K. Apoptosis in autoimmune diseases. Intern Med 2001;40:275-84.
44. Abou-Shousa SA, Salah E, Wagdy E. Study of P53 in peripheral blood and synovial mononuclear cells of rheumatoid arthritis and osteoarthritis patients and its relation to the degree of disease activity. Egypt J Immunol 2005;12:61-70.
45. Sun Y, Cheung HS. p53, proto-oncogene and rheumatoid arthritis. Semin Arthritis Rheum 2002;31:299-310.
46. Xu JX, Hoshida Y, Hongyo T, Sasaki T, Miyazato H, Tomita Y, et al. Analysis of p53 and Bak gene mutations in lymphoproliferative disorders developing in rheumatoid arthritis. J Cancer Res Clin Oncol 2007;133:125-33.
47. Hoshida Y, Hongyo T, Xu JX, Sasaki T, Tomita Y, Nomura T, et al. TP53 gene mutation, an unfavorable prognostic factor for malignant lymphomas in autoimmune diseases. Oncology 2005;69:175-83.
48. Shao L, Fujii H, Colmegna I, Oishi H, Goronzy JJ, Weyand CM. Deficiency of the DNA repair enzyme ATM in rheumatoid arthritis. J Exp Med 2009;206:1435-49.
49. Junta CM, Sandrin-Garcia P, Fachin-Saltoratto AL, Mello SS, Oliveira RD, Rassi DM, et al. Differential gene expression of peripheral blood mononuclear cells from rheumatoid arthritis patients may discriminate immunogenetic, pathogenic and treatment features. Immunology 2009;127:365-72.
50. Altindag O, Karakoc M, Kocyigit A, Celik H, Soran N. Increased DNA damage and oxidative stress in patients with rheumatoid arthritis. Clin Biochem 2007;40:167-71.